Published in Future Microbiol on October 01, 2011
Buruli Ulcer in Cameroon: The Development and Impact of the National Control Programme. PLoS Negl Trop Dis (2016) 1.41
Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis (2013) 0.98
Accelerated detection of mycolactone production and response to antibiotic treatment in a mouse model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis (2014) 0.87
Establishment of quantitative PCR (qPCR) and culture laboratory facilities in a field hospital in benin: 1-year results. J Clin Microbiol (2014) 0.84
Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis (2013) 0.81
Mycolactone-Dependent Depletion of Endothelial Cell Thrombomodulin Is Strongly Associated with Fibrin Deposition in Buruli Ulcer Lesions. PLoS Pathog (2015) 0.78
A theoretical model for the transmission dynamics of the Buruli ulcer with saturated treatment. Comput Math Methods Med (2014) 0.77
Clinical Features of Spontaneous Partial Healing During Mycobacterium ulcerans Infection. Open Forum Infect Dis (2016) 0.76
In Vitro Susceptibility of Mycobacterium ulcerans Isolates to Selected Antimicrobials. Can J Infect Dis Med Microbiol (2017) 0.75
Combatting AMR: photoactivatable ruthenium(ii)-isoniazid complex exhibits rapid selective antimycobacterial activity. Chem Sci (2016) 0.75
Efficacy of Rifampin Plus Clofazimine in a Murine Model of Mycobacterium ulcerans Disease. PLoS Negl Trop Dis (2015) 0.75
Challenges Associated with Management of Buruli Ulcer/Human Immunodeficiency Virus Coinfection in a Treatment Center in Ghana: A Case Series Study. Am J Trop Med Hyg (2015) 0.75
Tropical diseases and the poor: Neglected tropical diseases are a public health problem for developing and developed countries alike. EMBO Rep (2014) 0.75
Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science (1999) 6.37
Antimicrobial treatment for early, limited Mycobacterium ulcerans infection: a randomised controlled trial. Lancet (2010) 5.02
Mycobacterium ulcerans infection. Lancet (1999) 4.52
Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol (1997) 3.96
Identification and characterization of IS2404 and IS2606: two distinct repeated sequences for detection of Mycobacterium ulcerans by PCR. J Clin Microbiol (1999) 3.96
Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother (2005) 3.81
Giant plasmid-encoded polyketide synthases produce the macrolide toxin of Mycobacterium ulcerans. Proc Natl Acad Sci U S A (2004) 3.52
Reductive evolution and niche adaptation inferred from the genome of Mycobacterium ulcerans, the causative agent of Buruli ulcer. Genome Res (2007) 3.45
Promising clinical efficacy of streptomycin-rifampin combination for treatment of buruli ulcer (Mycobacterium ulcerans disease). Antimicrob Agents Chemother (2007) 3.41
A Mycobacterium ulcerans toxin, mycolactone, causes apoptosis in guinea pig ulcers and tissue culture cells. Infect Immun (2000) 3.27
Ecology and transmission of Buruli ulcer disease: a systematic review. PLoS Negl Trop Dis (2010) 2.98
Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease. Appl Environ Microbiol (1997) 2.88
Fluoroquinolone toxicity profiles: a review focusing on newer agents. Clin Infect Dis (1999) 2.62
A new mycobacterial infection in man. J Pathol Bacteriol (1948) 2.59
Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence. J Bacteriol (2000) 2.59
Buruli ulcer in Benin. Lancet (1990) 2.58
The pathogenic behavior of Mycobacterium ulcerans and Mycobacterium balnei in the mouse and the developing chick embryo. Am Rev Tuberc (1956) 2.57
Mycobacterium ulcerans in mosquitoes captured during outbreak of Buruli ulcer, southeastern Australia. Emerg Infect Dis (2007) 2.56
Direct detection and identification of Mycobacterium ulcerans in clinical specimens by PCR and oligonucleotide-specific capture plate hybridization. J Clin Microbiol (1997) 2.50
A simple PCR method for rapid genotype analysis of Mycobacterium ulcerans. J Clin Microbiol (2000) 2.43
Mycobacterium ulcerans disease. Bull World Health Organ (2005) 2.30
Epidemiology of Mycobacterium ulcerans infection (Buruli ulcer) at Kinyara, Uganda. Trans R Soc Trop Med Hyg (1971) 2.16
In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother (2006) 2.16
Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother (2002) 2.05
THE EXPERIMENTAL DISEASE THAT FOLLOWS THE INJECTION OF HUMAN LEPROSY BACILLI INTO FOOT-PADS OF MICE. J Exp Med (1960) 2.03
The inhibitory action of Mycobacterium ulcerans soluble factor on monocyte/T cell cytokine production and NF-kappa B function. J Immunol (1999) 2.03
A controlled trial of the treatment of Mycobacterium ulcerans infection with clofazimine. Lancet (1973) 2.02
First cultivation and characterization of Mycobacterium ulcerans from the environment. PLoS Negl Trop Dis (2008) 1.93
Partial purification and characterization of biological effects of a lipid toxin produced by Mycobacterium ulcerans. Infect Immun (1998) 1.93
Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother (2001) 1.90
Seasonal and regional dynamics of M. ulcerans transmission in environmental context: deciphering the role of water bugs as hosts and vectors. PLoS Negl Trop Dis (2010) 1.89
Oral treatment for Mycobacterium ulcerans infection: results from a pilot study in Benin. Clin Infect Dis (2011) 1.81
In vitro susceptibility of Mycobacterium ulcerans to clarithromycin. Antimicrob Agents Chemother (1998) 1.80
A major role for mammals in the ecology of Mycobacterium ulcerans. PLoS Negl Trop Dis (2010) 1.80
Activities of several antimicrobials against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother (2000) 1.79
Buruli ulcer: reductive evolution enhances pathogenicity of Mycobacterium ulcerans. Nat Rev Microbiol (2009) 1.77
"Paradoxical" immune-mediated reactions to Mycobacterium ulcerans during antibiotic treatment: a result of treatment success, not failure. Med J Aust (2009) 1.77
Clinical efficacy of combination of rifampin and streptomycin for treatment of Mycobacterium ulcerans disease. Antimicrob Agents Chemother (2010) 1.72
Mycobacterium ulcerans infection (with comments on pathogenesis). Int J Lepr (1966) 1.68
Mycobacterium ulcerans infection (Buruli ulcer): first reported patients in Togo. Br J Dermatol (1996) 1.67
Sensitivity of PCR targeting Mycobacterium ulcerans by use of fine-needle aspirates for diagnosis of Buruli ulcer. J Clin Microbiol (2009) 1.62
Mycobacterium ulcerans (Buruli) skin ulceration in Nigeria. Am J Trop Med Hyg (1976) 1.58
Mycobacterial skin ulcers in Uganda. Lancet (1961) 1.56
Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust (2007) 1.56
BCG vaccination against mycobacterium ulcerans infection (Buruli ulcer). First results of a trial in Uganda. Lancet (1969) 1.55
Isolation of three Mycobacterium ulcerans strains resistant to rifampin after experimental chemotherapy of mice. Antimicrob Agents Chemother (2003) 1.54
Toxin of Mycobacterium ulcerans. Production and effects in guinea pig skin. Arch Dermatol (1974) 1.53
Risk factors for Mycobacterium ulcerans infection, southeastern Australia. Emerg Infect Dis (2007) 1.53
Secondary Buruli ulcer skin lesions emerging several months after completion of chemotherapy: paradoxical reaction or evidence for immune protection? PLoS Negl Trop Dis (2011) 1.51
Response to treatment in a prospective cohort of patients with large ulcerated lesions suspected to be Buruli Ulcer (Mycobacterium ulcerans disease). PLoS Negl Trop Dis (2010) 1.48
Mycobacterium ulcerans infection in Ashanti region, Ghana. Trans R Soc Trop Med Hyg (1990) 1.48
A strategy for antagonizing quorum sensing. Mol Cell (2011) 1.47
[Mycobacterium ulcerans cutaneous infections: Buruli ulcers]. Med Trop (Mars) (1995) 1.44
Cytotoxic activity of Mycobacterium ulcerans. Infect Immun (1974) 1.42
The protective effect of BCG against Mycobacterium ulcerans disease: a controlled trial in an endemic area of Uganda. Trans R Soc Trop Med Hyg (1976) 1.42
Development of highly organized lymphoid structures in Buruli ulcer lesions after treatment with rifampicin and streptomycin. PLoS Negl Trop Dis (2007) 1.40
Functional analysis and annotation of the virulence plasmid pMUM001 from Mycobacterium ulcerans. Microbiology (2005) 1.38
Buruli ulcer: Advances in understanding Mycobacterium ulcerans infection. Dermatol Clin (2011) 1.37
Immunosuppressive properties of the soluble toxin from Mycobacterium ulcerans. J Infect Dis (1988) 1.33
BURULI (MYCOBACTERIAL) ULCERATION IN UGANDA. (A NEW FOCUS OF BURULI ULCER IN MADI DISTRICT, UGANDA): REPORT OF A FIELD STUDY. East Afr Med J (1965) 1.33
Mycobacterium ulcerans infections; response to chemotherapy in mice. Am Rev Tuberc (1957) 1.28
Pathogenetic mechanisms of the intracellular parasite Mycobacterium ulcerans leading to Buruli ulcer. Lancet Infect Dis (2009) 1.27
Mycobacterium ulcerans--a mini-review. J Med Microbiol (1999) 1.27
Rifampicin in experimental Mycobacterium ulcerans infection. J Med Microbiol (1972) 1.24
Distribution of Mycobacterium ulcerans infections in Zaire, including the report of new foci. Ann Soc Belg Med Trop (1974) 1.23
Immunosuppressive signature of cutaneous Mycobacterium ulcerans infection in the peripheral blood of patients with buruli ulcer disease. J Infect Dis (2009) 1.22
Activity of rifampicin on Mycobacterium ulcerans. Ann Soc Belg Med Trop (1975) 1.21
Mycolactone suppresses T cell responsiveness by altering both early signaling and posttranslational events. J Immunol (2009) 1.20
Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother (2007) 1.19
Laboratory diagnosis of Buruli ulcer disease. Future Microbiol (2010) 1.17
Buruli ulcer: a systemic disease. Clin Infect Dis (2003) 1.16
A pilot study of treatment of Buruli ulcer with rifampin and dapsone. Int J Infect Dis (2002) 1.14
Acute, oedematous Mycobacterium ulcerans infection in a farmer from far north Queensland. Med J Aust (2002) 1.14
Heat treatment of Mycobacterium ulcerans infections without surgical excision. Am J Trop Med Hyg (1974) 1.14
Studies on Mycobacterium ulcerans and Mycobacterium balnei. III. Growth in the semi-synthetic culture media of Dubos and drug sensitivity in vitro and in vivo. Aust J Exp Biol Med Sci (1954) 1.14
[TREATMENT OF EXPERIMENTAL INFECTION BY MYCOBACTERIUM ULCERANS AND MYCOBACTERIUM BALNEI IN MICE]. Ann Soc Belges Med Trop Parasitol Mycol (1965) 1.13
Buruli ulcer: differences in treatment outcome between two centres in Ghana. Acta Trop (2003) 1.11
All-oral antibiotic treatment for buruli ulcer: a report of four patients. PLoS Negl Trop Dis (2010) 1.11
The distribution of Buruli disease in Uganda. Trans R Soc Trop Med Hyg (1972) 1.09
Prophylactic effect of mycobacterium bovis BCG vaccination against osteomyelitis in children with Mycobacterium ulcerans disease (Buruli Ulcer). Clin Diagn Lab Immunol (2002) 1.08
Association of HIV infection and Mycobacterium ulcerans disease in Benin. AIDS (2008) 1.08
Serological evaluation of Mycobacterium ulcerans antigens identified by comparative genomics. PLoS Negl Trop Dis (2010) 1.08
Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice. PLoS Negl Trop Dis (2011) 1.07
Aggressive multifocal Buruli ulcer with associated osteomyelitis in an HIV-positive patient. Clin Exp Dermatol (2005) 1.07
Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother (2008) 1.06
Necrotic tropical ulcers and mycobacterial causative agents. Trop Geogr Med (1959) 1.05
Buruli ulcer disease: prospects for a vaccine. Med Microbiol Immunol (2009) 1.05
Phagocytosis of Mycobacterium ulcerans in the course of rifampicin and streptomycin chemotherapy in Buruli ulcer lesions. Br J Dermatol (2008) 1.02
Nerve damage in Mycobacterium ulcerans-infected mice: probable cause of painlessness in buruli ulcer. Am J Pathol (2006) 1.02
Disseminated Mycobacterium ulcerans disease in an HIV-positive patient: a case study. AIDS (2002) 1.02
Should antibiotics be given for Buruli ulcer? Lancet (2010) 1.01
Mycobacterium ulcerans triggers T-cell immunity followed by local and regional but not systemic immunosuppression. Infect Immun (2010) 1.00
Dynamics of the cytokine response to Mycobacterium ulcerans during antibiotic treatment for M. ulcerans disease (Buruli ulcer) in humans. Clin Vaccine Immunol (2008) 0.99
BCG-mediated protection against Mycobacterium ulcerans infection in the mouse. PLoS Negl Trop Dis (2011) 0.98
Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection. Antimicrob Agents Chemother (2010) 0.98
Severe multifocal form of buruli ulcer after streptomycin and rifampin treatment: comments on possible dissemination mechanisms. Am J Trop Med Hyg (2010) 0.98
TREATMENT OF MYCOBACTERIAL SKIN ULCERS IN UGANDA WITH A RIMINOPHENAZINE DERIVATIVE (B.663). Lancet (1964) 0.92
A booster vaccination with Mycobacterium bovis BCG does not increase the protective effect of the vaccine against experimental Mycobacterium ulcerans infection in mice. Infect Immun (2007) 0.91
Mycobacterium ulcerans infection: treatment with rifampin, hyperbaric oxygenation, and heat. Aviat Space Environ Med (1979) 0.89
Mycobacterium ulcerans in Liberia: a clinicopathologic study of 6 patients with Buruli ulcer. Acta Trop (1984) 0.87
Community-acquired meticillin-resistant Staphylococcus aureus: an emerging threat. Lancet Infect Dis (2005) 6.85
Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med (2003) 4.67
Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med (2009) 3.57
Moxifloxacin-containing regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med (2004) 3.45
Fluoroquinolones, tuberculosis, and resistance. Lancet Infect Dis (2003) 3.24
Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med (2007) 2.86
Dormancy phenotype displayed by extracellular Mycobacterium tuberculosis within artificial granulomas in mice. J Exp Med (2004) 2.46
Powerful bactericidal and sterilizing activity of a regimen containing PA-824, moxifloxacin, and pyrazinamide in a murine model of tuberculosis. Antimicrob Agents Chemother (2008) 2.29
Confronting multidrug-resistant tuberculosis. N Engl J Med (2012) 2.22
Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis. Am J Respir Crit Care Med (2005) 2.21
Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother (2009) 2.18
Combination chemotherapy with the nitroimidazopyran PA-824 and first-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2006) 2.18
Sterilizing activity of novel TMC207- and PA-824-containing regimens in a murine model of tuberculosis. Antimicrob Agents Chemother (2011) 1.99
Mouse model of necrotic tuberculosis granulomas develops hypoxic lesions. J Infect Dis (2011) 1.96
Potent twice-weekly rifapentine-containing regimens in murine tuberculosis. Am J Respir Crit Care Med (2006) 1.90
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial. Am J Respir Crit Care Med (2015) 1.86
Sterilizing activities of novel combinations lacking first- and second-line drugs in a murine model of tuberculosis. Antimicrob Agents Chemother (2012) 1.83
Contribution of moxifloxacin or levofloxacin in second-line regimens with or without continuation of pyrazinamide in murine tuberculosis. Am J Respir Crit Care Med (2013) 1.65
Dose-ranging comparison of rifampin and rifapentine in two pathologically distinct murine models of tuberculosis. Antimicrob Agents Chemother (2012) 1.63
Role of the dosR-dosS two-component regulatory system in Mycobacterium tuberculosis virulence in three animal models. Infect Immun (2008) 1.63
Substitution of rifapentine for rifampin during intensive phase treatment of pulmonary tuberculosis: study 29 of the tuberculosis trials consortium. J Infect Dis (2012) 1.53
Polymerized human Hb use in acute chest syndrome: a case report. Transfusion (2002) 1.51
Biphasic kill curve of isoniazid reveals the presence of drug-tolerant, not drug-resistant, Mycobacterium tuberculosis in the guinea pig. J Infect Dis (2009) 1.49
Comparison of the 'Denver regimen' against acute tuberculosis in the mouse and guinea pig. J Antimicrob Chemother (2010) 1.40
PA-824 exhibits time-dependent activity in a murine model of tuberculosis. Antimicrob Agents Chemother (2010) 1.38
Addition of PNU-100480 to first-line drugs shortens the time needed to cure murine tuberculosis. Am J Respir Crit Care Med (2009) 1.36
Rifapentine, moxifloxacin, or DNA vaccine improves treatment of latent tuberculosis in a mouse model. Am J Respir Crit Care Med (2005) 1.31
Short-course chemotherapy with TMC207 and rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med (2011) 1.24
Dose-dependent activity of pyrazinamide in animal models of intracellular and extracellular tuberculosis infections. Antimicrob Agents Chemother (2011) 1.24
Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor. Am J Respir Crit Care Med (2013) 1.23
Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobials. Proc Natl Acad Sci U S A (2012) 1.22
Short-course therapy with daily rifapentine in a murine model of latent tuberculosis infection. Am J Respir Crit Care Med (2009) 1.21
Assessment of clofazimine activity in a second-line regimen for tuberculosis in mice. Am J Respir Crit Care Med (2013) 1.20
Isoniazid or moxifloxacin in rifapentine-based regimens for experimental tuberculosis? Am J Respir Crit Care Med (2008) 1.19
World Health Organization group 5 drugs for the treatment of drug-resistant tuberculosis: unclear efficacy or untapped potential? J Infect Dis (2012) 1.15
Treatment of tuberculosis with rifamycin-containing regimens in immune-deficient mice. Am J Respir Crit Care Med (2011) 1.13
Emergence of fluoroquinolone resistance in Mycobacterium tuberculosis during continuously dosed moxifloxacin monotherapy in a mouse model. Antimicrob Agents Chemother (2005) 1.09
Autoluminescent Mycobacterium tuberculosis for rapid, real-time, non-invasive assessment of drug and vaccine efficacy. PLoS One (2012) 1.08
Activities of rifampin, Rifapentine and clarithromycin alone and in combination against mycobacterium ulcerans disease in mice. PLoS Negl Trop Dis (2011) 1.07
Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS (2013) 1.04
The impact of mouse passaging of Mycobacterium tuberculosis strains prior to virulence testing in the mouse and guinea pig aerosol models. PLoS One (2010) 1.03
Rapid assessment of antibacterial activity against Mycobacterium ulcerans by using recombinant luminescent strains. Antimicrob Agents Chemother (2010) 1.01
Effectiveness of tuberculosis chemotherapy correlates with resistance to Mycobacterium tuberculosis infection in animal models. J Antimicrob Chemother (2011) 0.99
BCG-mediated protection against Mycobacterium ulcerans infection in the mouse. PLoS Negl Trop Dis (2011) 0.98
Microbiological, histological, immunological, and toxin response to antibiotic treatment in the mouse model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis (2013) 0.98
Using bioluminescence to monitor treatment response in real time in mice with Mycobacterium ulcerans infection. Antimicrob Agents Chemother (2010) 0.98
Rifapentine is not more active than rifampin against chronic tuberculosis in guinea pigs. Antimicrob Agents Chemother (2012) 0.98
Latent tuberculosis infection. Semin Respir Crit Care Med (2004) 0.95
Potent rifamycin-sparing regimen cures guinea pig tuberculosis as rapidly as the standard regimen. Antimicrob Agents Chemother (2013) 0.94
Evaluation of new antituberculosis drugs in mouse models. Antimicrob Agents Chemother (2007) 0.88
The potent bactericidal activity of streptomycin in the guinea pig model of tuberculosis ceases due to the presence of persisters. J Antimicrob Chemother (2010) 0.86
Bactericidal activity does not predict sterilizing activity: the case of rifapentine in the murine model of Mycobacterium ulcerans disease. PLoS Negl Trop Dis (2013) 0.81
Improving existing tools for Mycobacterium xenopi treatment: assessment of drug combinations and characterization of mouse models of infection and chemotherapy. J Antimicrob Chemother (2012) 0.81
Activity of 5-chloro-pyrazinamide in mice infected with Mycobacterium tuberculosis or Mycobacterium bovis. Indian J Med Res (2012) 0.79
Activity of the fluoroquinolone DC-159a in the initial and continuation phases of treatment of murine tuberculosis. Antimicrob Agents Chemother (2011) 0.78
Modeling in vivo pharmacokinetics and pharmacodynamics of moxifloxacin therapy for Mycobacterium tuberculosis infection by using a novel cartridge system. Antimicrob Agents Chemother (2005) 0.78
Significance of macrolide resistance in Streptococcus pneumoniae. J Antimicrob Chemother (2003) 0.75
Reply to "Contradictory results with high-dosage rifamycin in mice and humans". Antimicrob Agents Chemother (2013) 0.75